ReviewCellular oncology (Dordrecht, Netherlands)2017
Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
Review in Cellular oncology (Dordrecht, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prognostic significance of systemic immune inflammation index for ovarian cancer: An updated systematic review and meta-analysis.Journal of ovarian research · 2025Pooled it
- The P7 peptide antagonizes bFGF-induced malignant behaviors of ovarian cancer by inhibiting MEK/ERK signaling pathway.Future science OA · 2026Article
- Knockdown TNF family prognosis index crucial gene PDE4B promoted PANoptosis of ovarian carcinoma cell:Based in vitro and in vivo experiments.Translational oncology · 2025Article
- Prognostic significance of chemotherapy response score in predicting outcomes for high-grade serous ovarian carcinoma patients undergoing neoadjuvant chemotherapy.Translational cancer research · 2025Article
- Emerging role of mucins in antibody drug conjugates for ovarian cancer therapy.Journal of ovarian research · 2024Review
- CircUBE2D2 regulates HMGB1 through miR-885-5p to promote ovarian cancer malignancy.Clinics (Sao Paulo, Brazil) · 2024Article
- High ratio of pCXCR4/CXCR4 tumor infiltrating immune cells in primary high grade ovarian cancer is indicative for response to chemotherapy.BMC cancer · 2022Article
- Article
- Tracing ovarian cancer research in Morocco: A bibliometric analysis.Gynecologic oncology reports · 2021Article
- Ovarian cancer in Morocco: Time to act is now.Gynecologic oncology reports · 2021Article
- Article
- Emerging Role of Metabolomics in Ovarian Cancer Diagnosis.Metabolites · 2020Review
- A nine-gene signature related to tumor microenvironment predicts overall survival with ovarian cancer.Aging · 2020Article
- Article
- CRISPR/Cas9-Mediated OC-2 Editing Inhibits the Tumor Growth and Angiogenesis of Ovarian Cancer.Frontiers in oncology · 2020Article
- High density of CD66b in primary high-grade ovarian cancer independently predicts response to chemotherapy.Journal of cancer research and clinical oncology · 2020Article
- Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin.Archives of gynecology and obstetrics · 2019Article
- Emerging ways to treat breast cancer: will promises be met?Cellular oncology (Dordrecht, Netherlands) · 2018Review
- Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma.Journal of cellular and molecular medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn spite of various treatment options currently available, ovarian cancer (OC) still remains a leading cause of death in women world-wide. Diagnosis at an early stage is one of the most important factors that determines survival. Current clinical diagnostic tools have, however, a limited efficacy in early OC detection. Therefore, there is a critical need for new (early) diagnostic biomarkers and tools. Through advances in genomic, proteomic and metabolomic techniques, several novel molecular OC biomarkers have recently been identified. These biomarkers are currently subject to validation. In addition, integration of genomic, proteomic and metabolomic data, in conjunction with epidemiologic and clinical data, is considered essential for obtaining useful results. Interesting recent work has already shown that specific diagnostic biomarkers, such as BRCA mutations, may have profound therapeutic implications. Here, we review the current state of OC research through literature and database searches, with a focus on various recently identified biomarkers via different technologies for the (early) diagnosis, prognosis and treatment of OC.
conclusionsMulti-biomarker panels accompanied by a meticulous determination of their sensitivity and specificity, as well their validation, using multivariate analyses will be critical for its clinical application, including early OC detection and tailor-made OC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.